Theresa May must take action against MPs peddling civil service conspiracy theories, says FDA

February 3rd 2018

Responding to accusations made by Jacob Rees-Mogg MP that civil servants working in HM Treasury are “fiddling figures” on Brexit, FDA General Secretary Dave Penman said:

“It is increasingly clear that Jacob Rees-Mogg has no concept of what public service is. Whilst civil servants are working flat out to deliver the best Brexit possible for the UK, he is prepared to peddle unsubstantiated conspiracy theories to further his own vision of Brexit, unconcerned if he damages the integrity of the civil service or the government in the process.

“One would have hoped a Parliamentarian would understand that before making such a profound accusation about the impartiality of the civil service, he should at least have some evidence.

“His refusal to apologise to Parliament for repeating an unfounded rumour on Thursday, followed by his reiteration of the claims today, is clear evidence that he’s prepared to sacrifice anyone or anything on the altar of his own ideology.

“This constant undermining of the civil service from within the Conservative Party has to stop. As Prime Minister and leader of that party, Theresa May needs to make an unequivocal statement in support of the civil service and take action against the parliamentarians and ministers making these unfounded accusations.”

Notes for editors

1. The FDA is the union for senior managers and professionals in public service, representing more than 18,000 members at grades HEO and above. Membership includes senior civil servants, Government policy advisors, prosecutors, diplomats, tax professionals, economists, solicitors and other professionals working across the Government and the NHS.

2. The FDA (formerly the First Division Association) should be referred to simply as "The FDA" and can be described as "the senior public servants' union".

3. The FDA can be found on Twitter @FDA_union and at www.fda.org.uk. General Secretary Dave Penman tweets as @FDAGenSec.

4. For further information contact the FDA Communications team on 020 7401 5589.